Delta4’s Participation at the 19th Annual Biotech in Europe Forum: A Landmark Experience
Delta4 was honored to attend the 19th Annual Biotech in Europe Forum in Basel, a premier event for the biotech and life science industry. This forum is renowned for its role as a key international platform for investment and partnership.
At the heart of the forum were insightful plenary sessions and workshops. These sessions, including the State of the Industry Overview Panel, Global VC & Private Equity Roundtable, and various therapeutic panels, showcased industry trends and fostered discussions on diverse topics like autoimmune diseases, neuroscience, and oncology. The forum also highlighted the dynamic nature of the biotech industry with panels on medical cannabis and longevity. It attracted a diverse mix of early-stage, late-stage, and public companies, investors, and pharma executives, included over 700 delegates, and facilitated more than 3000 one-to-one meetings.
Delta4 welcomed the opportunity to participate in this influential forum, which serves as a testament to the vibrant and collaborative spirit of the biotech industry.
What is the Biotech in Europe Forum (BEF)?
The Biotech in Europe Forum (BEF) is a prominent international event for the biotech and life science industry, focusing on investment and partnership opportunities. It gathers a diverse mix of private and public companies at various stages of growth, along with investors, analysts, money managers, and pharma licensing executives. The forum features plenary panels, workshops, and an abundance of networking opportunities, facilitating collaboration and innovation within the biotech sector. It’s recognized for its role in shaping industry trends and fostering connections among key industry players.
The Significance of the Biotech in Europe Forum
This event was significant for the global bio-pharma industry, focusing on key challenges in investment for 2019, as well as aspects of partnering and alliance management, and prospects for 2020. The panels and keynotes provided insights into the broader industry landscape and innovation in various therapeutic sectors.
Additionally, the forum offered a platform for early-stage/pre-IPO, late-stage, and public companies to connect with diverse key players and stakeholders across the industry. Facilitating thousands of one-to-one meetings and offering unparalleled networking and collaboration opportunities. The environment offers companies like Delta4 the chance to engage with a diverse group of brilliant individuals and organizations.
